Upregulated HDAC2 expression is associated with drug resistance, and HDAC2 depletion sensitizes multidrug-resistant cells (HT-29) to chemotherapeutic agents (5-FU or oxaliplatin) commonly used in CRC treatment. This evidence concerns the gene HDAC2 and colorectal carcinoma.